2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-101437
    Ralfinamide 133865-88-0 99.78%
    Ralfinamide (FCE-26742A) is an orally available Na+ blocker derived from α-aminoamide, with function of suppressing pain.
    Ralfinamide
  • HY-101640
    TPA 023 252977-51-8 99.76%
    TPA 023 is a GABAA α2/α3 subtype-selective agonist, with Ki of 0.19-0.41 nM.
    TPA 023
  • HY-101862
    CB-7921220 115453-99-1 ≥98.0%
    CB-7921220 is an adenylate cyclase inhibitor.
    CB-7921220
  • HY-102070
    NS13001 1063331-94-1 99.62%
    NS13001 is a potent, selective, orally active allosteric positive modulator of SK channels (small conductance calcium-activated potassium channels). The EC50s are 1.8 and 0.14 μM for SK2 and SK3, respectively. NS13001 holds promise as a potential therapeutic agent for treatment of spinocerebellar ataxia type 2 (SCA2) and possibly other cerebellar ataxias.
    NS13001
  • HY-103189
    VUF-5574 280570-45-8 ≥99.0%
    VUF-5574 is a selective antagonist of adenosine A3 receptor with a Ki of 4.03 nM for the recombinant human receptor.
    VUF-5574
  • HY-103207
    Amibegron hydrochloride 121524-09-2 ≥99.0%
    Amibegron hydrochloride is a selective β3-adrenoceptor agonist, with an EC50 of 3.5 nM for β-adrenoceptor in rat colon; Amibegron hydrochloride has anxiolytic and antidepressant activity.
    Amibegron hydrochloride
  • HY-103524
    Valerenic acid 3569-10-6 ≥99.0%
    Valerenic acid ((-)-Valerenic Acid), a sesquiterpenoid, is an orally active positive allosteric modulator of GABAA receptors. Valerenic acid is also a partial agonist of the 5-HT5a receptor. Valerenic acid mediates anxiolytic activity via GABAA receptors containing the β3 subunit. Valerenic acid also exhibits potent antioxidant properties.
    Valerenic acid
  • HY-103528
    SCS 3232-36-8 99.64%
    SCS (Salicylidene salicylhydrazide) is a potent, allosteric and selective inhibitor of β1-containing GABAA receptors with an IC50 of 32 nM against α2β1γ1θ by VIPR measurement. SCS is also a chelator of metal ions.
    SCS
  • HY-105005
    Crisdesalazine 927685-43-6 98.92%
    Crisdesalazine (AAD-2004) is an anti-inflammatory agent that simultaneously blocks inflammation mediated by free radicals and prostaglandin E2 (PGE2). Crisdesalazine (AAD-2004) can be used to study neurodegeneration in amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
    Crisdesalazine
  • HY-105860
    Selurampanel 912574-69-7 99.41%
    Selurampanel (BGG 492) is an orally active and competitive AMPA receptor antagonist with an IC50 of 190 nM. Selurampanel has reasonable blood-brain barrier penetration. Selurampanel can be used for epilepsy research.
    Selurampanel
  • HY-106000
    GSK239512 720691-69-0 99.09%
    GSK239512 is a potent and brain penetrated H3 receptor antagonist. GSK239512 can be used for the research of mild-to-moderate Alzheimer's disease (AD).
    GSK239512
  • HY-106157
    Donitriptan 170912-52-4 98.06%
    Donitriptan is a potent, high efficacy agonist at 5-HT1B/1D receptors with pKis of 9.4 and 9.3, respectively.
    Donitriptan
  • HY-106246
    Pruvanserin 443144-26-1 99.27%
    Pruvanserin (EMD 281014 free acid) is a selective 5-HT2A receptor antagonist. Pruvanserin alleviates tactile allodynia in diabetic rats. Pruvanserin can also be used for research of insomnia.
    Pruvanserin
  • HY-107198
    (2S)-6-Prenylnaringenin 68236-13-5 99.84%
    (2S)-6-Prenylnaringenin is the most efficient compound in forebrain. (2S)-6-Prenylnaringenin acts as a GABAA positive allosteric modulator at α+β- binding interface.
    (2S)-6-Prenylnaringenin
  • HY-107501
    (Rac)-1-Oleoyl lysophosphatidic acid sodium 22556-62-3 ≥98.0%
    (Rac)-1-Oleoyl lysophosphatidic acid ((Rac)-1-Oleoyl-sn-glycero-3-phosphate) sodium is the racemic isomer of 1-Oleoyl lysophosphatidic acid sodium (HY-107614).
    (Rac)-1-Oleoyl lysophosphatidic acid sodium
  • HY-107660
    SIRT2-IN-8 115687-05-3 99.32%
    SIRT2-IN-8 is a potent SIRT2 inhibitor. SIRT2-IN-8 can be used for Huntington’s and Parkinson’s diseases research.
    SIRT2-IN-8
  • HY-107682
    TQS 353483-92-8 99.84%
    TQS is a α7 nicotinic acetylcholine receptor (nAChR) positive allosteric modulator. TQS can be used for the research of neuroinflammatory pain.
    TQS
  • HY-107706
    Co 101244 hydrochloride 193356-17-1 99.87%
    Co 101244 (PD 174494) hydrochloride is a NR2B-containing NMDA receptor antagonist.
    Co 101244 hydrochloride
  • HY-107711
    DQP-1105 380560-89-4 98.00%
    DQP-1105 is a potent noncompetitive NMDA receptor antagonist. DQP-1105 inhibits GluN2C- and GluN2D-containing receptors (IC50=7.0 and 2.7 μM, respectively). The IC50 values are at least 50-fold lower than those for recombinant GluN2A-, GluN2B-, GluA1-, or GluK2-containing receptors.
    DQP-1105
  • HY-107759
    Butabindide oxalate 185213-03-0 ≥98.0%
    Butabindide (UCL-1397) oxalate is a potent, selective tripeptidvl peptidase II (TPP II) inhibitor with Ki values of 7 nM and 10 μM for TPP II and TPP I, respectively. Butabindide oxalate inhibits TPP II to protect CCK-8 against inactivation.
    Butabindide oxalate
Cat. No. Product Name / Synonyms Application Reactivity